Wave Life Sciences Ltd Expected To Post A Loss Of 31 Cents A Share: Earnings Preview

Wave Life Sciences

28/07/2026 13:56

WAVE Life Sciences Ltd WVE.OQ WVE.O is expected to  show a fall in quarterly revenue when it reports  results on July 30 for the period ending June 30 2026
The  Singapore-based   company is expected to report a 19.0% decrease in revenue to $7.05 million from $8.7 million a year ago, according to the mean estimate from 14 analysts, based on LSEG data.
​LSEG's mean analyst estimate for WAVE Life Sciences Ltd is for a loss of 31 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for WAVE Life Sciences Ltd is $21.00, about 254.7% above its last closing price of $5.92
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.33
-0.33
-0.13
Beat
60.3
Dec. 31 2026
-0.27
-0.27
-0.30
Missed
-11.1
Sep. 30 2025
-0.29
-0.30
-0.32
Missed
-7.3​
Jun. 30 2025
-0.30
-0.29
-0.31
Missed
-6.7
​​Mar. 31 2025
-0.26
-0.26
-0.29
Missed
-11.1
Dec. 31 2024
-0.16
-0.18
0.17
Beat
193.4​
Sep. 30 2024
-0.27
-0.28
-0.47
Missed
-65.9
Jun. 30 2024
-0.19
-0.21
-0.25
Missed
-21
This summary was machine generated July 28 at 12:56 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)